{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:58:25Z","timestamp":1781643505755,"version":"3.54.5"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005713","name":"Technische Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Meningiomas (MNGs) occur in different histopathological subtypes. The WHO grading system classifies a subset as grade 2 and 3, indicating a more aggressive course. Recent advances in risk stratification introduces an integrated molecular-morphological score (IntS), offering improved risk prediction over the traditional WHO classification. This study aims to evaluate the prognostic utility of IntS in the context of the timing of adjuvant radiotherapy (RT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study analyzed 55 patients with histologically diagnosed WHO grade 2 and 3 MNG treated with adjuvant RT. Molecular analyses using Illumina 450k Human BeadChip and Illumina 850k EPIC stratified patients into 3 risk groups (low, intermediate and high) using an integrated model that combines WHO grading, Copy Number Variations (CNVs), and Methylation Families (MF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After 5 years a local failure-free survival (LFFS) rate of 0% in MF-malignant MNG contrasts with a LFFS rate of 77% and 58% in MF-benign and MF-intermediate MNG. A significant correlation between CNVs and LFFS was also observed in the adjuvant setting. The IntS model revealed distinct 5-year LFFS disparities across different risk categories, underscoring the impact of combined morphological and molecular characteristics on outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The integration of DNA-methylation and CNV-profiles into the IntS unified risk score offer an enhanced prognostic differentiation of MNG patients. This approach shows a promising direction for guiding the optimal timing of adjuvant RT, offering a path toward more tailored treatment strategies for meningiomas.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11060-026-05508-4","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T10:52:40Z","timestamp":1774263160000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic impact of radiotherapy timing in WHO grade 2 and 3 meningiomas utilizing an integrated molecular-morphologic classification"],"prefix":"10.1007","volume":"177","author":[{"given":"Claire","family":"Delbridge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen X.","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hielscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Wiestler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Negwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Schenck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Peeken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Diehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Borm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Krieg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaywan A.","family":"Aftahy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia M.","family":"Leiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Schmidt-Graf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meike","family":"Mitsd\u00f6rffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Yakushev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Von Deimling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Gempt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie E.","family":"Combs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Sahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Bernhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"5508_CR1","doi-asserted-by":"publisher","unstructured":"Yarabarla V et al (2023) Intracranial meningiomas: an update of the 2021 World Health Organization classifications and review of management with a focus on radiation therapy. Front Oncol 13 https:\/\/doi.org\/10.3389\/fonc.2023.1137849","DOI":"10.3389\/fonc.2023.1137849"},{"key":"5508_CR2","doi-asserted-by":"publisher","unstructured":"Szulzewsky F, Thirimanne HN, Holland EC (2024) Meningioma: current updates on genetics, classification, and mouse modeling. Upsala J Med Sci 129 https:\/\/doi.org\/10.48101\/ujms.v129.10579","DOI":"10.48101\/ujms.v129.10579"},{"key":"5508_CR3","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/neuonc\/noab150","volume":"23","author":"R Goldbrunner","year":"2021","unstructured":"Goldbrunner R et al (2021) EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol 23:1821\u20131834","journal-title":"Neuro Oncol"},{"key":"5508_CR4","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.1200\/JCO.21.00784","volume":"39","author":"SLN Maas","year":"2021","unstructured":"Maas SLN et al (2021) Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. J Clin Oncol 39:3839\u20133852","journal-title":"J Clin Oncol"},{"key":"5508_CR5","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S1470-2045(17)30155-9","volume":"18","author":"F Sahm","year":"2017","unstructured":"Sahm F et al (2017) DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol 18:682\u2013694","journal-title":"Lancet Oncol"},{"key":"5508_CR6","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41588-022-01061-8","volume":"54","author":"A Choudhury","year":"2022","unstructured":"Choudhury A et al (2022) Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. Nat Genet 54:649\u2013659","journal-title":"Nat Genet"},{"key":"5508_CR7","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1093\/neuonc\/noz061","volume":"21","author":"F Nassiri","year":"2019","unstructured":"Nassiri F et al (2019) DNA methylation profiling to predict recurrence risk in meningioma: Development and validation of a nomogram to optimize clinical management. Neuro Oncol 21:901\u2013910","journal-title":"Neuro Oncol"},{"key":"5508_CR8","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00401-017-1678-x","volume":"133","author":"A Olar","year":"2017","unstructured":"Olar A et al (2017) Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma. Acta Neuropathol 133:431\u2013444","journal-title":"Acta Neuropathol"},{"key":"5508_CR9","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1093\/neuonc\/noab213","volume":"24","author":"J Driver","year":"2022","unstructured":"Driver J et al (2022) A molecularly integrated grade for meningioma. Neuro Oncol 24:796\u2013808","journal-title":"Neuro Oncol"},{"key":"5508_CR10","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1038\/s41591-023-02586-z","volume":"29","author":"WC Chen","year":"2023","unstructured":"Chen WC et al (2023) Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. Nat Med 29:3067\u20133076","journal-title":"Nat Med"},{"key":"5508_CR11","doi-asserted-by":"crossref","unstructured":"Pan PC et al (2021) Outcomes following upfront radiation versus monitoring in atypical meningiomas: 16-year experience at a tertiary medical center. Neurooncol Adv 3","DOI":"10.1093\/noajnl\/vdab094"},{"key":"5508_CR12","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jocn.2017.08.023","volume":"46","author":"A Dohm","year":"2017","unstructured":"Dohm A et al (2017) Early or late radiotherapy following gross or subtotal resection for atypical meningiomas: Clinical outcomes and local control. J Clin Neurosci 46:90\u201398","journal-title":"J Clin Neurosci"},{"key":"5508_CR13","doi-asserted-by":"crossref","unstructured":"Ehret F et al (2024) Clinical implications of DNA methylation-based integrated classification of histologically defined grade 2 meningiomas. Acta Neuropathol Commun 12","DOI":"10.1186\/s40478-024-01739-6"},{"key":"5508_CR14","doi-asserted-by":"crossref","unstructured":"Deng MY et al (2023) Analysis of recurrence probability following radiotherapy in patients with CNS WHO grade 2 meningioma using integrated molecular-morphologic classification. Neurooncol Adv 5","DOI":"10.1093\/noajnl\/vdad059"},{"key":"5508_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03167-4","author":"JZ Wang","year":"2024","unstructured":"Wang JZ et al (2024) Molecular classification to refine surgical and radiotherapeutic decision-making in meningioma. Nat Med. https:\/\/doi.org\/10.1038\/s41591-024-03167-4","journal-title":"Nat Med"},{"key":"5508_CR16","doi-asserted-by":"publisher","unstructured":"Maas SLN et al (2023) Independent prognostic impact of DNA methylation class and chromosome 1p loss in WHO grade 2 and 3 meningioma undergoing adjuvant high-dose radiotherapy: comprehensive molecular analysis of EORTC 22042\u201326042. Acta Neuropathol 146 837\u2013840 https:\/\/doi.org\/10.1007\/s00401-023-02642-5","DOI":"10.1007\/s00401-023-02642-5"},{"key":"5508_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3171\/2016.11.JNS161170","volume":"129","author":"L Rogers","year":"2017","unstructured":"Rogers L et al (2017) Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. J Neurosurg 129:35\u201347","journal-title":"J Neurosurg"},{"key":"5508_CR18","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.radonc.2018.06.018","volume":"128","author":"DC Weber","year":"2018","unstructured":"Weber DC et al (2018) Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: A phase-II parallel non-randomized and observation study (EORTC 22042\u201326042). Radiotherapy et Oncol 128:260\u2013265","journal-title":"Radiotherapy et Oncol"},{"key":"5508_CR19","doi-asserted-by":"publisher","unstructured":"Chun SW et al (2021) Adjuvant radiotherapy versus observation following gross total resection for atypical meningioma: a systematic review and meta-analysis. RadiatOncol 16 https:\/\/doi.org\/10.1186\/s13014-021-01759-9","DOI":"10.1186\/s13014-021-01759-9"},{"key":"5508_CR20","doi-asserted-by":"publisher","first-page":"111935","DOI":"10.1016\/j.jocn.2026.111935","volume":"147","author":"L Tang","year":"2026","unstructured":"Tang L et al (2026) Timing of adjuvant radiotherapy impacts overall survival for atypical intracranial meningiomas: a National Cancer Database (NCDB) analysis. J Clin Neurosci 147:111935","journal-title":"J Clin Neurosci"},{"key":"5508_CR21","doi-asserted-by":"crossref","unstructured":"Mirian C et al (2026) Fractionated radiotherapy adjuvant to surgery of WHO-2 meningioma with and without gross total resection: a multicenter, retrospective cohort study of 1,452 patients. J Neurooncol 176","DOI":"10.1007\/s11060-025-05349-7"},{"key":"5508_CR22","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN et al (2021) The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro Oncol 23:1231\u20131251","journal-title":"Neuro Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05508-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05508-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05508-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:42:28Z","timestamp":1781642548000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05508-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["5508"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05508-4","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of the Technical University in Munich, Germany (645\/21 S-KK). The requirement of informed consent was waived by the ethical committee due to the retrospective nature of this study. All examinations and evaluations were performed following institutional guidelines and the Declaration of Helsinki of 1975 in its most recent and updated version.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"AvD and FS are co-founders and shareholders of Heidelberg Epignostix GmbH.All other authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}